Magnetic Nanoparticles for Brain Imaging via Nasal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PET imaging methods for neurological diseases are hindered by the high cost of PET apparatuses and the short half-life of radioactive contrast mediums, requiring large-scale drug production facilities, and lack a suitable contrast medium for imaging abnormal proteins in the brain.
Innovation Solution
Development of magnetic nanoparticles comprising magnetic iron oxide particles with gold fine particles supported on their surface, bonded to a polymer chain with a directed neurodegenerative disease-related protein, specifically designed for nasal administration to accumulate at sites of abnormal protein deposition in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PET imaging is used to observe abnormal proteins in the brain, then imaging capability is improved, but device cost and infrastructure requirements increase significantly
Solution Approach 1:
The patent replaces the complex PET imaging system with a simpler MRI-compatible magnetic nanoparticle system. Instead of using radioactive tracers and PET scanners, the invention uses magnetically labeled nanoparticles that can be detected by widely available MRI equipment, thereby substituting a complex mechanical/radioactive system with a simpler magnetic field-based system while maintaining imaging capability
Solution Approach 2:
The patent changes the detection parameter from radioactive signal detection (PET) to magnetic signal detection (MRI). By modifying the contrast mechanism from radioactivity to magnetic properties, the system becomes compatible with existing MRI infrastructure, reducing device cost and complexity requirements while preserving the ability to image abnormal proteins in the brain
2Measurement precision
If radioactive contrast mediums are used for PET imaging, then imaging function is achieved, but the short half-life requires large-scale drug production facilities near medical institutions
Solution Approach 1:
The patent replaces short-lived radioactive contrast agents with stable magnetic nanoparticle contrast agents. The magnetic nanoparticles have no expiration date and do not require the complex infrastructure of large-scale radioactive drug production facilities, eliminating the need for nearby manufacturing plants while maintaining imaging functionality
Solution Approach 2:
The invention substitutes radioactive decay-based contrast mechanisms with magnetic property-based contrast mechanisms. This replacement eliminates the need for radioactive isotope production, purification, and quality control infrastructure, significantly simplifying manufacturing requirements while preserving the ability to provide imaging function
3Ease of operation
If nanoparticles are nasally administered to reach the brain, then non-invasive delivery is achieved, but particles of 100 nm or more mostly migrate to blood and liver rather than the brain
Solution Approach 1:
The patent applies local quality by creating a heterogeneous nanoparticle structure with different functional components at different locations: the magnetic iron oxide core provides magnetic properties, the gold fine particles provide surface functionality, and the polymer chain with directed groups provides specific binding capability. This localized functional differentiation enables the particle to navigate nasal barriers while maintaining brain targeting capability
Solution Approach 2:
The invention uses a composite material structure combining magnetic iron oxide particles, gold fine particles, and polymer chains with directed groups. This composite structure integrates multiple functions: magnetic responsiveness for imaging, gold surface for functionalization, and polymer-directed groups for specific protein binding. The composite nature allows the particle to overcome nasal barriers and achieve reliable brain delivery that homogeneous particles cannot achieve
4Reliability
If a magnetic nanoparticle with specific configuration is developed, then brain accumulation capability is improved, but particle structure complexity increases
Solution Approach 1:
The patent segments the nanoparticle into distinct functional modules: a magnetic iron oxide core for magnetic properties and imaging, gold fine particles for surface functionality, and polymer chains with directed groups for specific protein binding. This segmentation allows each component to be optimized independently while working together to achieve reliable brain accumulation, managing complexity through functional modularity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables effective imaging of abnormal proteins in the brain by accumulating at sites of deposition, overcoming the limitations of existing PET imaging methods and providing a non-radioactive, cost-effective contrast medium for neurological disease diagnosis.
Implementation Method 1
a magnetic iron oxide particle
Data Source
AI summary
The purpose of the present invention is to provide a contrast medium using a paramagnetic metal that accumulates at an abnormal protein deposition or aggregation site in the brain. Magnetic nanoparticles for image diagnosis which comprise magnetic iron oxide particles, gold fine particles supported on the surface of the magnetic iron oxide particles, a polymer chain attached to the gold fine particles and a molecule directing for a neurodegenerative disease-related protein and attached to at least a part of the polymer chain, and which are to be administered transnasally. These magnetic nanoparticles for image diagnosis are useful as an active ingredient of a contrast medium that accumulates at an abnormal protein deposition or aggregation site in the brain.